You just read:

German Federal Joint Committee recognises added benefit of once-daily LIXIANA® (edoxaban) for preventing stroke and systemic embolism in patients with non-valvular atrial fibrillation

News provided by

Daiichi Sankyo Company, Limited

22 Jan, 2016, 12:00 GMT